{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:53:56Z","timestamp":1790679236062,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["119187"],"award-info":[{"award-number":["119187"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Midwest Athletes Against Childhood Cancer (MACC) Fund AVROBIO, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Enzyme and chaperone therapies are used to treat Fabry disease. Such treatments are expensive and require intrusive biweekly infusions; they are also not particularly efficacious. In this pilot, single-arm study (NCT02800070), five adult males with Type 1 (classical) phenotype Fabry disease were infused with autologous lentivirus-transduced, CD34\n                    <jats:sup>+<\/jats:sup>\n                    -selected, hematopoietic stem\/progenitor cells engineered to express alpha-galactosidase A (\u03b1-gal A). Safety and toxicity are the primary endpoints. The non-myeloablative preparative regimen consisted of intravenous melphalan. No serious adverse events (AEs) are attributable to the investigational product. All patients produced \u03b1-gal A to near normal levels within one week. Vector is detected in peripheral blood and bone marrow cells, plasma and leukocytes demonstrate \u03b1-gal A activity within or above the reference range, and reductions in plasma and urine globotriaosylceramide (Gb\n                    <jats:sub>3<\/jats:sub>\n                    ) and globotriaosylsphingosine (lyso-Gb\n                    <jats:sub>3<\/jats:sub>\n                    ) are seen. While the study and evaluations are still ongoing, the first patient is nearly three years post-infusion. Three patients have elected to discontinue enzyme therapy.\n                  <\/jats:p>","DOI":"10.1038\/s41467-021-21371-5","type":"journal-article","created":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T06:04:11Z","timestamp":1614233051000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":112,"title":["Lentivirus-mediated gene therapy for Fabry disease"],"prefix":"10.1038","volume":"12","author":[{"given":"Aneal","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5528-8150","authenticated-orcid":false,"given":"Dwayne L.","family":"Barber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Anthony","family":"Rupar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack W.","family":"Rip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Auray-Blais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Boutin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"O\u2019Hoski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristy","family":"Gargulak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William M.","family":"McKillop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Wasim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaye","family":"LeMoine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly","family":"Jelinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahsan","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Prokopishyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal F.","family":"Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Couban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1615-2274","authenticated-orcid":false,"given":"Peter R.","family":"Duggan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armand","family":"Keating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Foley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8165-8995","authenticated-orcid":false,"given":"Jeffrey A.","family":"Medin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,25]]},"reference":[{"key":"21371_CR1","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","volume":"276","author":"RO Brady","year":"1967","unstructured":"Brady, R. O. et al. Enzymatic defect in Fabry\u2019s disease. Ceramidetrihexosidase deficiency. N. Engl. J. Med. 276, 1163\u20131167 (1967).","journal-title":"N. Engl. J. Med"},{"key":"21371_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41572-018-0025-4","volume":"4","author":"FM Platt","year":"2018","unstructured":"Platt, F. M., d\u2019Azzo, A., Davidson, B. L., Neufeld, E. F. & Tifft, C. J. Lysosomal storage diseases. Nat. Rev. Dis. Prim. 4, 27 (2018).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"21371_CR3","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1073\/pnas.0712309105","volume":"105","author":"JM Aerts","year":"2008","unstructured":"Aerts, J. M. et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc. Natl Acad. Sci. USA 105, 2812\u20132817 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"21371_CR4","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1021\/ac203433e","volume":"84","author":"C Auray-Blais","year":"2012","unstructured":"Auray-Blais, C. et al. Urinary globotriaosylsphingosine-related biomarkers for Fabry disease targeted by metabolomics. Anal. Chem. 84, 2745\u20132753 (2012).","journal-title":"Anal. Chem."},{"key":"21371_CR5","doi-asserted-by":"publisher","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","volume":"138","author":"RJ Desnick","year":"2003","unstructured":"Desnick, R. J. et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann. Intern. Med. 138, 338\u2013346 (2003).","journal-title":"Ann. Intern. Med."},{"key":"21371_CR6","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","volume":"11","author":"S Waldek","year":"2009","unstructured":"Waldek, S., Patel, M. R., Banikazemi, M., Lemay, R. & Lee, P. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet. Med. 11, 790\u2013796 (2009).","journal-title":"Genet. Med."},{"key":"21371_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng, C. M. et al. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry\u2019s disease. N. Engl. J. Med. 345, 9\u201316 (2001).","journal-title":"N. Engl. J. Med."},{"key":"21371_CR8","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1510198","volume":"375","author":"DP Germain","year":"2016","unstructured":"Germain, D. P. et al. Treatment of Fabry\u2019s disease with the pharmacologic chaperone migalastat. N. Engl. J. Med. 375, 545\u2013555 (2016).","journal-title":"N. Engl. J. Med."},{"key":"21371_CR9","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann, R. et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285, 2743\u20132749 (2001).","journal-title":"JAMA"},{"key":"21371_CR10","first-page":"CD006663","volume":"7","author":"R El Dib","year":"2016","unstructured":"El Dib, R. et al. Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst. Rev. 7, CD006663 (2016).","journal-title":"Cochrane Database Syst. Rev."},{"key":"21371_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-8-47","volume":"8","author":"SM Rombach","year":"2013","unstructured":"Rombach, S. M. et al. Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. Orphanet J. Rare Dis. 8, 47 (2013).","journal-title":"Orphanet J. Rare Dis."},{"key":"21371_CR12","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1086\/318809","volume":"68","author":"CM Eng","year":"2001","unstructured":"Eng, C. M. et al. A phase 1\/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am. J. Hum. Genet. 68, 711\u2013722 (2001).","journal-title":"Am. J. Hum. Genet"},{"key":"21371_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-015-0253-6","volume":"10","author":"M Biegstraaten","year":"2015","unstructured":"Biegstraaten, M. et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J. Rare Dis. 10, 36 (2015).","journal-title":"Orphanet J. Rare Dis."},{"key":"21371_CR14","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","volume":"123","author":"A Ortiz","year":"2018","unstructured":"Ortiz, A. et al. Fabry disease revisited: management and treatment recommendations for adult patients. Mol. Genet. Metab. 123, 416\u2013427 (2018).","journal-title":"Mol. Genet. Metab."},{"key":"21371_CR15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ymgme.2018.06.004","volume":"124","author":"C Wanner","year":"2018","unstructured":"Wanner, C. et al. European expert consensus statement on therapeutic goals in Fabry disease. Mol. Genet. Metab. 124, 189\u2013203 (2018).","journal-title":"Mol. Genet. Metab."},{"key":"21371_CR16","doi-asserted-by":"publisher","first-page":"7917","DOI":"10.1073\/pnas.93.15.7917","volume":"93","author":"JA Medin","year":"1996","unstructured":"Medin, J. A. et al. Correction in trans for Fabry disease: expression, secretion and uptake of alpha-galactosidase A in patient-derived cells driven by a high-titer recombinant retroviral vector. Proc. Natl Acad. Sci. USA 93, 7917\u20137922 (1996).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"21371_CR17","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1089\/10430349950017293","volume":"10","author":"T Takenaka","year":"1999","unstructured":"Takenaka, T., Qin, G., Brady, R. O. & Medin, J. A. Circulating alpha-galactosidase A derived from transduced bone marrow cells: relevance for corrective gene transfer for Fabry disease. Hum. Gene Ther. 10, 1931\u20131939 (1999).","journal-title":"Hum. Gene Ther."},{"key":"21371_CR18","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2310\/6650.2002.33432","volume":"50","author":"GA Ashley","year":"2002","unstructured":"Ashley, G. A., Desnick, R. J., Gordon, R. E. & Gordon, J. W. High overexpression of the human alpha-galactosidase A gene driven by its promoter in transgenic mice: implications for the treatment of Fabry disease. J. Invest. Med. 50, 185\u2013192 (2002).","journal-title":"J. Invest. Med."},{"key":"21371_CR19","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S0925-4439(98)00012-X","volume":"1406","author":"R Kase","year":"1998","unstructured":"Kase, R. et al. Immunohistochemical characterization of transgenic mice highly expressing human lysosomal alpha-galactosidase. Biochim. Biophys. Acta 1406, 260\u2013266 (1998).","journal-title":"Biochim. Biophys. Acta"},{"key":"21371_CR20","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.omtm.2017.05.003","volume":"5","author":"J Huang","year":"2017","unstructured":"Huang, J. et al. Lentivector iterations and pre-clinical scale-up\/toxicity testing: targeting mobilized CD34(+) cells for correction of Fabry disease. Mol. Ther. Methods Clin. Dev. 5, 241\u2013258 (2017).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"21371_CR21","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/gim.2018.31","volume":"21","author":"H Maruyama","year":"2019","unstructured":"Maruyama, H. et al. Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis. Genet. Med. 21, 44\u201352 (2019).","journal-title":"Genet. Med."},{"key":"21371_CR22","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/cge.12590","volume":"89","author":"J Politei","year":"2016","unstructured":"Politei, J., Schenone, A. B., Cabrera, G., Heguilen, R. & Szlago, M. Fabry disease and enzyme replacement therapy in classic patients with same mutation: different formulations\u2013different outcome? Clin. Genet. 89, 88\u201392 (2016).","journal-title":"Clin. Genet"},{"key":"21371_CR23","doi-asserted-by":"publisher","first-page":"1233158","DOI":"10.1126\/science.1233158","volume":"341","author":"A Biffi","year":"2013","unstructured":"Biffi, A. et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 341, 1233158 (2013).","journal-title":"Science"},{"key":"21371_CR24","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1056\/NEJMoa1003548","volume":"363","author":"K Boztug","year":"2010","unstructured":"Boztug, K. et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N. Engl. J. Med. 363, 1918\u20131927 (2010).","journal-title":"N. Engl. J. Med."},{"key":"21371_CR25","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1056\/NEJMoa1609677","volume":"376","author":"JA Ribeil","year":"2017","unstructured":"Ribeil, J. A. et al. Gene therapy in a patient with sickle cell disease. N. Engl. J. Med. 376, 848\u2013855 (2017).","journal-title":"N. Engl. J. Med."},{"key":"21371_CR26","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1056\/NEJMoa1705342","volume":"378","author":"AA Thompson","year":"2018","unstructured":"Thompson, A. A. et al. Gene therapy in patients with transfusion-dependent beta-thalassemia. N. Engl. J. Med. 378, 1479\u20131493 (2018).","journal-title":"N. Engl. J. Med."},{"key":"21371_CR27","doi-asserted-by":"publisher","first-page":"e239","DOI":"10.1016\/S2352-3026(19)30021-3","volume":"6","author":"F Ferrua","year":"2019","unstructured":"Ferrua, F. et al. Lentiviral haemopoietic stem\/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1\/2 clinical study. Lancet Haematol. 6, e239\u2013e253 (2019).","journal-title":"Lancet Haematol."},{"key":"21371_CR28","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1253\/circj.70.1503","volume":"70","author":"M Yoshimitsu","year":"2006","unstructured":"Yoshimitsu, M. et al. Correction of cardiac abnormalities in Fabry mice by direct intraventricular injection of a recombinant lentiviral vector that engineers expression of alpha-galactosidase A. Circ. J. 70, 1503\u20131508 (2006).","journal-title":"Circ. J."},{"key":"21371_CR29","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1182\/blood.V11.5.436.436","volume":"11","author":"WA Skoog","year":"1956","unstructured":"Skoog, W. A. & Beck, W. S. Studies on the fibrinogen, dextran and phytohemagglutinin methods of isolating leukocytes. Blood 11, 436\u2013454 (1956).","journal-title":"Blood"},{"key":"21371_CR30","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.cca.2014.08.002","volume":"438","author":"C Auray-Blais","year":"2015","unstructured":"Auray-Blais, C. et al. Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry. Clin. Chim. Acta 438, 195\u2013204 (2015).","journal-title":"Clin. Chim. Acta"},{"key":"21371_CR31","doi-asserted-by":"publisher","first-page":"3476","DOI":"10.1021\/ac404000d","volume":"86","author":"M Boutin","year":"2014","unstructured":"Boutin, M. & Auray-Blais, C. Multiplex tandem mass spectrometry analysis of novel plasma lyso-Gb(3)-related analogues in Fabry disease. Anal. Chem. 86, 3476\u20133483 (2014).","journal-title":"Anal. Chem."},{"key":"21371_CR32","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1021\/ac303033v","volume":"85","author":"P Lavoie","year":"2013","unstructured":"Lavoie, P., Boutin, M. & Auray-Blais, C. Multiplex analysis of novel urinary lyso-Gb3-related biomarkers for Fabry disease by tandem mass spectrometry. Anal. Chem. 85, 1743\u20131752 (2013).","journal-title":"Anal. Chem."},{"key":"21371_CR33","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jjcc.2010.08.003","volume":"57","author":"CJ Lee","year":"2011","unstructured":"Lee, C. J., Fan, X., Guo, X. & Medin, J. A. Promoter-specific lentivectors for long-term, cardiac-directed therapy of Fabry disease. J. Cardiol. 57, 115\u2013122 (2011).","journal-title":"J. Cardiol."},{"key":"21371_CR34","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.cjca.2018.03.011","volume":"34","author":"H Hazari","year":"2018","unstructured":"Hazari, H. et al. Comparison of cardiac magnetic resonance imaging and echocardiography in assessment of left ventricular hypertrophy in Fabry disease. Can. J. Cardiol. 34, 1041\u20131047 (2018).","journal-title":"Can. J. Cardiol."},{"key":"21371_CR35","doi-asserted-by":"crossref","unstructured":"Kurtzberg J. et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N. Engl. J. Med. 335(3), 157\u2013166 (1996).","DOI":"10.1056\/NEJM199607183350303"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21371-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21371-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21371-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T05:57:37Z","timestamp":1669960657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21371-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,25]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["21371"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-21371-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,25]]},"assertion":[{"value":"5 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.K. received grants, consulting fees, revenue distribution agreement, speaker fees and travel support with AVROBIO, Inc. as well as revenue distribution agreement with University Health Network regarding gene therapy using technology from this work. D.L.B. and J.H. were partially paid from a Sponsored Research Agreement\u2014AVROBIO, Inc. C. A. Rupar has the following financial relationships to disclose: the Biochemical Genetics clinical diagnostic laboratory at his home institution is contracted by AVROBIO, Inc. to assay enzymes on a fee for service basis. He is the laboratory director but receives no personal compensation. C.A.-B. has received a service contract and honoraria for biomarker analysis with AVROBIO, Inc., grant from CIHR. K.G. had travel paid for by AVROBIO, Inc. S.W. has received nonfinancial support from Sanofi-Genzyme, nonfinancial support from Takeda Pharmaceuticals (formerly Shire HGT), personal fees and nonfinancial support from Amicus Therapeutics. K.L. has received travel grant and honorarium from Amicus Therapies; travel grant and speaker fees from Sanofi-Genzyme; travel grant, consulting fees and speaker fees from Takeda Pharmaceuticals; medical advisor to the Canadian Fabry Disease Association. C.F.M. has received grants, personal fees, and nonfinancial support from Takeda Pharmaceuticals (previously Shire HGT), grants, personal fees and nonfinancial support from Sanofi-Genzyme, nonfinancial support from Amicus Therapeutics. A.K. has received consultancy fees from AVROBIO, Inc. unrelated to this study. M.L.W. has received research grants, consulting fees, speaker fees and travel support with Amicus Therapeutics, Protalix, Sanofi-Genzyme and Takeda, revenue distribution agreement with University Health Network regarding gene therapy using technology from this work. J.A.M. has the following financial relationships to disclose: SAB\u2014Rapa Therapeutics. Honoraria\u2014Sanofi-Genzyme, Shire. Co-Founder\u2014AVROBIO, Inc. Shareholder\u2014AVROBIO, Inc. Grants from Canadian Institutes of Health Research and Kidney Foundation of Canada and AVROBIO, Inc. M.B., A.C., P.R.D., R.F., D.H.F., G.F., S.J., W.M.M., P.O., N.P., and J.W.R. have no financial relationships to disclose in relation to this trial.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1178"}}